Patients with sickle cell disease have abnormally shaped red blood cells, which can hinder blood flow and limit oxygen delivery to the body. Recent clinical trials showed patients taking Endari had fewer hospital visits and shorter length of stays for sickle cell complications than those taking a placebo.
“Until now, only one other drug was approved for patients living with this serious, debilitating condition,” said Richard Pazdur, MD, acting director of the FDA’s Office of
Hematology and Oncology Products and director of the agency’s Oncology Center of Excellence.
Emmaus Medical did not say when Endari will hit the market.
More articles on supply chain:
How Trump’s efforts to lower drug prices affect the industry — 4 questions on a possible executive order
Suburban Hospital wants to compete with MedStar Georgetown for liver transplants
Why supply chain leaders should practice unlearning
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.